<DOC>
	<DOCNO>NCT00500032</DOCNO>
	<brief_summary>Subjects complete study 6108A1-500 , experimental meningoccal B vaccine placebo administer , approach inclusion study purely blood draw . The serum use assay development .</brief_summary>
	<brief_title>Blood Collection Use Serological Assay Development From Healthy Adult Volunteers</brief_title>
	<detailed_description>The purpose protocol analyze collection blood volume ( approximately 200 470 mL per bleed ) volunteer donor previously complete study 6108A1-500 . As , inclusion exclusion criterion consistent Australian Red Cross guideline blood donation . The 6108A1-500 study ongoing , double-blind , ascending-dose , randomize , placebo-controlled trial ass safety tolerability ascend dos rLP2086 aluminum phosphate ( AlPO4 ) adjuvant , healthy adult age 18 25 year . Upon completion participation 6108A1-500 study , subject approach participate blood sample study . The site participate blood sample study site participate 6108A1-500 study .</detailed_description>
	<criteria>Main 1 . Completed study 6108A1500 . 2 . Hemoglobin level ≥12.0 ≤16.5 g/dL female subject ≥13.0 ≤18.5 g/dL male subject . 3 . Body weight ≥45 ≤120 kg . 4 . Systolic blood pressure &gt; 90 &lt; 180 mm Hg . 5 . Diastolic blood pressure &gt; 60 &lt; 100 mm Hg . 6 . Able contact telephone . 7 . For female subject : negative urine pregnancy test unless subject surgically sterile . Main 1 . Bleeding diathesis condition associate prolonged bleeding time . 2 . Prior antibiotic use ( within 14 day ) . 3 . Any clinically significant chronic disease , investigator 's judgment may worsen blood draw .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Adult</keyword>
</DOC>